Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: michael s. who wrote (3659)	1/25/1998 6:02:00 PM
From: David S.	Read Replies (1) \| Respond to of 6136

to all: this is an experiment - I am going to post something that most of us would not find offensive, and we'll see if any people who participate on this thread lose their temper. OK, here we go... Today, a football team will win the Super Bowl.

To: michael s. who wrote (3659)	1/27/1998 12:20:00 AM
From: JOHN W.	Respond to of 6136

"Experiment Combines Drug With HIV Vaccine" Reuters (01/24/98) University of Pennsylvania researchers plan to combine an HIV vaccine with proven triple-drug therapy, hoping that the vaccine will work better in patients who have the virus under control. Under the trial, the vaccine--Apollon Inc.'s Malvern--will be administered to 21 patients receiving triple-drug treatments. Malvern, which uses four pieces of HIV's DNA, has shown promise in trials but has not yet been proven to slow infection. Dr. Rob McGregor, director of clinical AIDS research at the University of Pennsylvania, believes that an enhanced response may be achieved in patients whose immune systems have stabilized.